How is clonus assessed and what does it indicate in suspected hypertensive disorders of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clonus Assessment in Hypertensive Disorders of Pregnancy

Clonus should be assessed as part of routine maternal monitoring in preeclampsia by briskly dorsiflexing the foot with the knee flexed and observing for rhythmic, involuntary muscle contractions; sustained clonus (≥3 beats) indicates hyperreflexia and signals increased risk of eclamptic seizures, warranting immediate consideration for magnesium sulfate prophylaxis. 1

What is Clonus?

Clonus is a series of rhythmic, involuntary muscular contractions that occur in response to sudden stretching of a muscle. In the context of preeclampsia, it represents hyperreflexia—an exaggerated deep tendon reflex response that reflects central nervous system irritability and increased risk of progression to eclampsia (seizures).

How to Measure Clonus

Technique:

  • Position the patient with the knee flexed at approximately 90 degrees
  • Grasp the foot firmly around the metatarsals
  • Briskly dorsiflex the foot (push the foot upward toward the shin) and maintain gentle sustained pressure
  • Observe for rhythmic beats: Normal response shows no beats or 1-2 transient beats; sustained clonus (≥3 beats) is abnormal
  • Test both ankles for comparison

Clinical Significance:

The presence of sustained clonus indicates:

  • Heightened neuromuscular excitability
  • Increased risk of eclamptic seizures
  • Need for closer monitoring and potential magnesium sulfate administration

Integration into Preeclampsia Monitoring

Maternal monitoring in preeclampsia must include clinical assessment of clonus as part of the neurological examination 1. This assessment should be performed:

  • At initial diagnosis of preeclampsia
  • During ongoing inpatient monitoring
  • When evaluating for severe features
  • Before and during magnesium sulfate therapy

When Clonus Triggers Action:

Women with preeclampsia who have hypertension with neurological signs or symptoms (including sustained clonus) should receive magnesium sulfate for convulsion prophylaxis 1.

Additional abnormal neurological features warranting delivery include:

  • Severe intractable headache
  • Repeated visual scotomata
  • Convulsions
  • Sustained clonus with other severe features

Common Pitfalls

  • Confusing transient beats with sustained clonus: 1-2 beats can be normal, especially in anxious patients; only sustained rhythmic contractions (≥3 beats) are pathological
  • Inadequate dorsiflexion force: Too gentle a stimulus may miss hyperreflexia
  • Testing with the knee extended: This can produce false results; the knee must be flexed
  • Ignoring unilateral findings: Even unilateral sustained clonus warrants concern
  • Failing to document: Serial assessments help track disease progression

The assessment of clonus is a simple bedside test that provides critical information about central nervous system involvement in preeclampsia and helps guide decisions about seizure prophylaxis and timing of delivery.

Related Questions

What are the differences between gestational hypertension, preeclampsia, and eclampsia?
In a 38‑week pregnant patient with blood pressure 150/100 mm Hg and no signs or symptoms of pre‑eclampsia, what is the recommended management?
In a 24‑week pregnant patient with methamphetamine intoxication, severe hypertension (190/137 mm Hg) and tachycardia (140 bpm), what are the immediate next steps in management?
What is the appropriate management for a 37‑week pregnant woman with hypertension (BP up to 157/98 mm Hg), proteinuria (~37 mg/L urine albumin), elevated alanine aminotransferase, and low serum magnesium?
What is the appropriate management of chronic hypertension in a 27-year-old woman at 12 weeks gestation on labetalol with a blood pressure of 159/91 mm Hg?
For a patient with HIV and anaplastic large cell lymphoma on bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) and pembrolizumab (Pifeltro), CD4 count 163 cells/µL, HIV RNA 320 copies/mL, currently receiving trimethoprim‑sulfamethoxazole (single‑strength) daily, acyclovir 400 mg twice daily, levofloxacin 500 mg daily and fluconazole 200 mg daily (ANC now 4.9 ×10⁹/L), should we continue trimethoprim‑sulfamethoxazole and acyclovir, discontinue levofloxacin and fluconazole, and repeat the viral load in 4–8 weeks while maintaining the current ART regimen?
Should Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) be limited to a 60‑day course in a patient with HIV, low CD4 count, detectable viral load, and receiving pembrolizumab for anaplastic large‑cell lymphoma?
What specific considerations should be taken into account in the management of an electrical burn to the hand?
Should Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) be continued indefinitely in a patient with HIV after jaw mass excision for lymphoma, or can it be stopped after 60 days?
Which antibiotic is appropriate for a healthy 20-year-old woman presenting with dysuria and a urinalysis showing numerous white blood cells?
What are the differential diagnoses for a cystic neoplasm in the pancreas?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.